PubRank

A Study to Determine the Safety, Tolerability and Efficacy NW-3509A in Patients With Chronic Schizophrenia

Clinical Trial ID NCT02624167

PubWeight™ 0.00‹?›

🔗 Visit the ClinicalTrials.gov page for NCT02624167

Top papers

Rank Title Journal Year PubWeight™‹?›
1 The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992 144.02
2 The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987 51.07
3 Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005 28.99
4 Columbia Classification Algorithm of Suicide Assessment (C-CASA): classification of suicidal events in the FDA's pediatric suicidal risk analysis of antidepressants. Am J Psychiatry 2007 6.35
5 Assessing depression in schizophrenia: the Calgary Depression Scale. Br J Psychiatry Suppl 1993 3.24
6 Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia. Neuropsychopharmacology 2003 2.46
7 Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. Clin Pharmacokinet 2009 2.37
8 Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update. Clin Pharmacol Ther 2014 1.84
9 Prediction of outcome in schizophrenia. III. Five-year outcome and its predictors. Arch Gen Psychiatry 1977 1.81
10 Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II. Clin Pharmacokinet 2009 1.73
11 The efficacy of lamotrigine in clozapine-resistant schizophrenia: a systematic review and meta-analysis. Schizophr Res 2009 1.66
12 Manual for the Extrapyramidal Symptom Rating Scale (ESRS). Schizophr Res 2005 1.66
13 Voltage-gated sodium channels in neurological disorders. CNS Neurol Disord Drug Targets 2008 1.23
14 Pharmacogenetics of debrisoquine and its use as a marker for CYP2D6 hydroxylation capacity. Pharmacogenomics 2009 0.85
15 Schizophrenia and valproate. Psychopharmacol Bull 2003 0.80
16 Polymorphism in CYP2D6 and CYP2C19, members of the cytochrome P450 mixed-function oxidase system, in the metabolism of psychotropic drugs. J Intern Med 2015 0.77
Next 100